ApoE Genotyping as a Progression-Rate Biomarker in Phase II Disease-Modification Trials for Alzheimer's Disease

Pharmacogenomics Journal - United Kingdom
doi 10.1038/tpj.2009.58
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Serum Interleukin (IL)-15 as a Biomarker of Alzheimer's Disease

PLoS ONE
Multidisciplinary
2015English

Extravascular Fibrinogen in the White Matter of Alzheimer's Disease and Normal Aged Brains: Implications for Fibrinogen as a Biomarker for Alzheimer's Disease

Brain Pathology
Forensic MedicineNeurosciencePathologyNeurology
2019English

Considering the APOE Locus in Polygenic Scores for Alzheimer's Disease

2019English

Changes in the EEG Amplitude as a Biomarker for Early Detection of Alzheimer's Disease

2016English

Correction for Holland Et Al., Subregional Neuroanatomical Change as a Biomarker for Alzheimer's Disease

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2010English

Visuospatial Perception: An Emerging Biomarker for Alzheimer's Disease

Journal of Alzheimer's Disease
GerontologyClinical PsychologyMental HealthPsychiatryGeriatricsMedicineNeuroscience
2012English

Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease

Canadian Journal of Kidney Health and Disease
Nephrology
2017English

A Mathematical Model of Alzheimer's Disease and the Apoe Gene

ASTIN Bulletin
AccountingEconomicsEconometricsFinance
2000English

Phase II Cancer Clinical Trials for Biomarker-Guided Treatments

Journal of Biopharmaceutical Statistics
StatisticsProbabilityPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy